Karyopharm Therapeutics Inc (KPTI)

Apr 07, 2025

Karyopharm therapeutics CEO Richard Paulson sells $916 in stock By Investing.com - Investing.com South Africa

Apr 07, 2025

Apr 07, 2025

Karyopharm therapeutics CEO Richard Paulson sells $916 in stock - Investing.com

Apr 07, 2025

Apr 02, 2025

Karyopharm Therapeutics (NASDAQ:KPTI) Shares Pass Below Two Hundred Day Moving Average – Time to Sell? - Defense World

Apr 02, 2025

Apr 01, 2025

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire

Apr 01, 2025

Mar 19, 2025

Piper Sandler cuts Karyopharm stock target to $15 from $75 - Investing.com

Mar 19, 2025

Mar 19, 2025

Piper Sandler cuts Karyopharm stock target to $15 from $75 By Investing.com - Investing.com South Africa

Mar 19, 2025

Mar 11, 2025

Karyopharm Therapeutics (NASDAQ:KPTI) Shares Cross Below 200-Day Moving Average – Time to Sell? - Defense World

Mar 11, 2025

Mar 07, 2025

Karyopharm Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025

Mar 06, 2025

Karyopharm therapeutics SVP sells $17,567 in shares By Investing.com - Investing.com Canada

Mar 06, 2025

Mar 06, 2025

Karyopharm therapeutics CEO Richard Paulson sells $73,555 in stock By Investing.com - Investing.com South Africa

Mar 06, 2025

Mar 06, 2025

Karyopharm Therapeutics Executives Sell Shares - TradingView

Mar 06, 2025

Mar 06, 2025

Karyopharm therapeutics CEO Richard Paulson sells $73,555 in stock - Investing.com

Mar 06, 2025

Mar 06, 2025

Karyopharm therapeutics SVP sells $17,567 in shares - Investing.com India

Mar 06, 2025

Mar 04, 2025

Karyopharm Therapeutics (NASDAQ:KPTI) Price Target Lowered to $54.00 at Robert W. Baird - Defense World

Mar 04, 2025

Mar 03, 2025

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc. To Contact The Firm - ACCESS Newswire

Mar 03, 2025

Mar 03, 2025

Karyopharm Therapeutics Inc. (KPTI), Mallinckrodt plc (MNK) & National General Holdings Corp. (NGHC)Bronstein, Gewirtz & Grossman, LLCClass Action Reminder - ACCESS Newswire

Mar 03, 2025

Mar 03, 2025

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MENAFN.COM

Mar 03, 2025

Mar 03, 2025

KPTI Stock Touches 52-Week Low at $7.58 Amid Market Challenges - Investing.com

Mar 03, 2025

Mar 02, 2025

Karyopharm Therapeutics (KPTI) Projected to Post Earnings on Thursday - MarketBeat

Mar 02, 2025

Mar 01, 2025

International Myeloma Foundation (IMF) Celebrates Myeloma Milestones for 2025 Myeloma Action Month - GlobeNewswire Inc.

Mar 01, 2025

Mar 01, 2025

Karyopharm Therapeutics (NASDAQ:KPTI) Price Target Raised to $56.00 - Defense World

Mar 01, 2025

Mar 01, 2025

HC Wainwright Forecasts Strong Price Appreciation for Karyopharm Therapeutics (NASDAQ:KPTI) Stock - MarketBeat

Mar 01, 2025

Feb 28, 2025

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Down 93.1% in February - MarketBeat

Feb 28, 2025

Feb 28, 2025

Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price Down 9%What's Next? - MarketBeat

Feb 28, 2025

Feb 28, 2025

Karyopharm Therapeutics (NASDAQ:KPTI) Sees Large Volume Increase After Analyst Upgrade - MarketBeat

Feb 28, 2025

Feb 28, 2025

HC Wainwright Issues Optimistic Estimate for KPTI Earnings - MarketBeat

Feb 28, 2025

Feb 28, 2025

FY2025 Earnings Estimate for KPTI Issued By Leerink Partnrs - MarketBeat

Feb 28, 2025

Feb 27, 2025

Karyopharm Therapeutics (KPTI) to Release Quarterly Earnings on Thursday - Defense World

Feb 27, 2025

Feb 26, 2025

Karyopharm Therapeutics Inc.’s SWOT analysis: biotech firm’s stock faces pivotal year - Investing.com India

Feb 26, 2025

Feb 26, 2025

Karyopharm Therapeutics Inc.’s SWOT analysis: biotech firm’s stock faces pivotal year By Investing.com - Investing.com South Africa

Feb 26, 2025

Feb 25, 2025

Research Analysts Issue Forecasts for KPTI Q1 Earnings - MarketBeat

Feb 25, 2025

Feb 25, 2025

Royal Bank of Canada Reaffirms Outperform Rating for Karyopharm Therapeutics (NASDAQ:KPTI) - MarketBeat

Feb 25, 2025

Feb 25, 2025

Karyopharm announces 1-for-15 reverse stock split - MSN

Feb 25, 2025

Feb 25, 2025

Karyopharm enacts 1-for-15 reverse stock split to boost price - Investing.com Australia

Feb 25, 2025

Feb 24, 2025

Karyopharm enacts reverse stock split to meet Nasdaq standards By Investing.com - Investing.com South Africa

Feb 24, 2025

Feb 24, 2025

Karyopharm enacts reverse stock split to meet Nasdaq standards - Investing.com

Feb 24, 2025

Feb 24, 2025

Karyopharm Unveils 1-for-15 Reverse Stock Split, Effective February 25, 2025 - Nasdaq

Feb 24, 2025

Feb 24, 2025

Karyopharm Therapeutics to Implement 1-for-15 Reverse Stock Split -February 24, 2025 at 01:18 pm EST - Marketscreener.com

Feb 24, 2025

Feb 24, 2025

Karyopharm Announces 1-for-15 Reverse Stock Split - Citizentribune

Feb 24, 2025

Feb 24, 2025

Karyopharm enacts 1-for-15 reverse stock split to boost price By Investing.com - Investing.com South Africa

Feb 24, 2025

Feb 24, 2025

Leerink Partnrs Has Pessimistic View of KPTI FY2025 Earnings - Defense World

Feb 24, 2025

Feb 24, 2025

Research Analysts Offer Predictions for KPTI Q1 Earnings - Defense World

Feb 24, 2025

Feb 23, 2025

What is Leerink Partnrs’ Estimate for KPTI Q1 Earnings? - The AM Reporter

Feb 23, 2025

Feb 23, 2025

Karyopharm Therapeutics’ (KPTI) “Buy” Rating Reiterated at HC Wainwright - Defense World

Feb 23, 2025

Feb 22, 2025

Karyopharm’s 2024 Earnings and Clinical Progress - TipRanks

Feb 22, 2025

Feb 21, 2025

HC Wainwright Reaffirms "Buy" Rating for Karyopharm Therapeutics (NASDAQ:KPTI) - MarketBeat

Feb 21, 2025

Feb 21, 2025

Karyopharm targets $1B revenue potential for Selinexor in myelofibrosis amid Phase 3 progress - MSN

Feb 21, 2025

Feb 20, 2025

H.C. Wainwright maintains Buy on Karyopharm with $7 target By Investing.com - Investing.com South Africa

Feb 20, 2025

Feb 20, 2025

Karyopharm’s Earnings Call: Growth Amid Financial Challenges - TipRanks

Feb 20, 2025